| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCRL6 |
| Uniprot No | Q6DN72 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-307aa |
| 氨基酸序列 | LYLQAWPNPVFEGDALTLRCQGWKNTPLSQVKFYRDGKFLHFSKENQTLS MGAATVQSRGQYSCSGQVMYIPQTFTQTSETAMVQVQELFPPPVLSAIPS PEPREGSLVTLRCQTKLHPLRSALRLLFSFHKDGHTLQDRGPHPELCIPG AKEGDSGLYWCEVAPEGGQVQKQSPQLEVRVQAPVSRPVLTLHHGPADPA VGDMVQLLCEAQRGSPPILYSFYLDEKIVGNHSAPCGGTTSLLFPVKSEQ DAGNYSCEAENSVSRERSEPKKLSLKGSQVLFTPASNW |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与FCRL6重组蛋白相关的研究文献摘要概述：
1. **文献名称**：*Structural and functional characterization of FCRL6. an immune receptor expressed by cytotoxic lymphocytes*
**作者**：Davis RS et al.
**摘要**：本研究解析了重组FCRL6蛋白的晶体结构，揭示其与MHC II类分子的潜在结合能力，并通过体外实验证明其在调节NK细胞和T细胞活化中的抑制作用。
2. **文献名称**：*FCRL6 regulates immune synapse formation and T cell signaling in tumor microenvironment*
**作者**：Li H et al.
**摘要**：利用重组FCRL6蛋白进行功能研究，发现其通过干扰T细胞受体(TCR)信号通路，抑制肿瘤浸润淋巴细胞的活性，提示其作为肿瘤免疫治疗靶点的可能性。
3. **文献名称**：*Recombinant FCRL6 protein as a novel biomarker for chronic lymphocytic leukemia*
**作者**：Smith C et al.
**摘要**：开发了重组FCRL6蛋白检测方法，发现其在慢性淋巴细胞白血病(CLL)患者中异常高表达，可能作为疾病进展及预后的潜在标志物。
4. **文献名称**：*Expression and purification of functional FCRL6 extracellular domain in mammalian cell systems*
**作者**：Wang Y et al.
**摘要**：报道了在HEK293细胞中高效表达具有生物活性的重组FCRL6胞外区蛋白的方法，并通过流式细胞术验证其与B细胞表面配体的结合特性。
(注：以上文献为虚拟示例，实际文献需通过PubMed/Google Scholar检索关键词“FCRL6 recombinant protein”获取。)
**Background of FCRL6 Recombinant Protein**
FCRL6 (Fc receptor-like 6) is a transmembrane protein belonging to the Fc receptor-like (FCRL) family, which shares structural homology with classical Fc receptors but lacks direct Fc-binding capacity. Primarily expressed on cytotoxic lymphocytes, including subsets of natural killer (NK) cells and effector CD8+ T cells, FCRL6 is implicated in modulating immune responses. Its extracellular region contains immunoglobulin-like domains, while its cytoplasmic tail harbors immunoreceptor tyrosine-based inhibitory motifs (ITIMs), suggesting a regulatory role in cell signaling.
FCRL6 has garnered attention for its differential expression in lymphoid malignancies and autoimmune disorders, positioning it as a potential biomarker or therapeutic target. Studies suggest it may influence immune cell activation, tolerance, and cytotoxicity, though its precise ligands and signaling mechanisms remain under investigation. Recombinant FCRL6 protein, typically produced in mammalian expression systems with tags (e.g., Fc or His tags), retains the functional epitopes of the native protein. This engineered tool enables researchers to study FCRL6-ligand interactions, receptor oligomerization, and downstream signaling pathways.
Applications of FCRL6 recombinant protein include *in vitro* binding assays, antibody development, and functional studies exploring its role in immune evasion, particularly in tumor microenvironments. Its utility extends to drug discovery, where it aids in screening inhibitors or agonists to modulate FCRL6-mediated immune responses. By elucidating FCRL6's biology, researchers aim to advance therapies for cancers, autoimmune diseases, and infections, leveraging its dual potential as a diagnostic marker and immunomodulatory target.
×
